Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Skinvisible (SKVI) Cash & Equivalents (2016 - 2025)

Skinvisible's Cash & Equivalents history spans 15 years, with the latest figure at $645.0 for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 5.39% year-over-year to $645.0; the TTM value through Sep 2025 reached $645.0, up 5.39%, while the annual FY2024 figure was $10336.0, 1063.96% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $645.0 at Skinvisible, up from $120.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $160336.0 in Q2 2022 and bottomed at $120.0 in Q2 2025.
  • The 5-year median for Cash & Equivalents is $12667.0 (2021), against an average of $34296.2.
  • The largest annual shift saw Cash & Equivalents crashed 99.43% in 2023 before it skyrocketed 1063.96% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $66037.0 in 2021, then rose by 23.23% to $81378.0 in 2022, then plummeted by 98.91% to $888.0 in 2023, then surged by 1063.96% to $10336.0 in 2024, then crashed by 93.76% to $645.0 in 2025.
  • Per Business Quant, the three most recent readings for SKVI's Cash & Equivalents are $645.0 (Q3 2025), $120.0 (Q2 2025), and $13396.0 (Q1 2025).